Basic Science Research (Genomics, Proteomics and Metabolomics)


Trairak Pisitkun, MD

Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand


Although advanced cancer therapeutics have already existed in recent years, the high failure and low survival rate are still existent. The primary reason for the disappointment of those treatments is possibly from the high heterogeneity of genetic background in different types of cancer as well as in different individual patients. So, the unmet need for new treatment options that can be tailored for each person is urgently required. Cancer immunotherapy has come to be a robust approach for several types of cancer because it exploits our immune systems to attack cancer cells, so it is a promising strategy to eliminate cancer. To develop personalized cancer immunotherapy such as cancer vaccine, it is essential to characterize the specific targets which can be selectively recognized by the immune system. Cancer cells classically contain a high number of somatic mutations that do not emerge in normal cells. Those mutated peptides can be presented on the tumor cell surface in complex with human leukocyte antigen (HLA) class I protein; this HLA-mutated-peptide complex could potentially be immunogenic and recognized by T cells as a neoantigen. Therefore, identification of neoantigens is an essential step to improve the development of cancer vaccine approach and help in the prediction of patient response to checkpoint inhibitors. Here we discuss our progress in the development of personalized neoantigen-based cancer immunotherapy.

Event Hours(1)

  • Lotus 1-2

    11:10 am – 12:00 pm

    1. Prof. Dr. M.R.Jisnuson Svasti (CRA)
    2. Prof. Manop Pithukpakorn (SI)
    3. Asst. Prof. Natini Jinawath (Rama)
    4. Dr. Trairak Pisitkun (CU)